SAN FRANCISCO--(BUSINESS WIRE)--Sep. 7, 2016--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, foals, and high value horses, announced today that it has
signed an exclusive supply and distribution agreement (the “Agreement”)
for Croton lechleri botanical extract (the “botanical extract”)
with Fresno, California-based Integrated Animal Nutrition and Health
Inc. for dairy cattle and pigs in the Chinese marketplace.
The Agreement was executed following the positive results, which Jaguar
announced this past July, of two studies to evaluate the safety and
effectiveness of the botanical extract in piglets. The terms of the
Agreement specify annual minimum purchase amounts that are required to
maintain exclusivity, and state that Integrated Animal Nutrition and
Health Inc. is responsible for all activities and costs to obtain all
required product registrations, marketing authorizations, and customs
clearances for the Chinese market.
The piglet studies were sponsored by Integrated Animal Nutrition and
Health Inc., involved more than 1,000 animals, and took place earlier
this year at pig farms in China. The results indicate resolution and
cure rates ranging from 60-99%, and a benefit on prophylaxis of diarrhea.
“We have seen great interest in Jaguar’s Croton lechleri
botanical extract in China and believe that the market potential for the
product is substantial,” commented Dr. Kai Hang Chen, founder and CEO of
Integrated Animal Nutrition and Health Inc.
Lisa Conte, Jaguar’s president and CEO, stated, “We are very happy about
the exclusive supply and distribution agreement we’ve entered into with
Integrated Animal Nutrition and Health Inc., and about the opportunity
to leverage our first-in-class technology in this very important Chinese
market. As we work to expand our commercialization efforts, we intend to
seek out additional opportunities to enter key international markets.”
According to the Minnesota-based Institute for Agriculture and Trade
Policy, swine production was expected to reach 723 million head in 2014
in China, where pork is still the main protein source for many
consumers. In 2015 there were an estimated 15.6 million dairy cattle in
China, according to Index Muni. China, with the world’s largest
population, has been experiencing an increase in demand for dairy
products as a result of sharply increasing income levels, fast-changing
food habits, the desire of parents to feed their babies high-protein
formula, and the loosening in 2015 of China’s longstanding one-child
policy, among other factors.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. SB-300 is Jaguar’s prescription drug product candidate for the
treatment of gastrointestinal ulcers in horses. Canalevia™
and SB-300 contain ingredients isolated and purified from the Croton
lechleri tree, which is sustainably harvested. Neonorm™
Calf and Neonorm™ Foal are the Company’s lead
non-prescription products. Neonorm™ is a standardized
botanical extract derived from the Croton lechleri tree. Canalevia™
and Neonorm™ are distinct products that act at the same last
step in a physiological pathway generally present in mammals. Jaguar has
nine active investigational new animal drug applications, or INADs,
filed with the FDA and intends to develop species-specific formulations
of Neonorm™ in six additional target species, formulations of
SB-300 in horses, and Canalevia™ for cats and dogs.
For more information, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding annual minimum purchase
amounts that are required for Integrated Animal Nutrition and Health
Inc. to maintain exclusivity under the terms of the Agreement, the
ability of Integrated Animal Nutrition and Health Inc. to obtain all
required product registrations, marketing authorizations, and customs
clearance for the Chinese market, Jaguar’s opportunity to leverage its
technology in the Chinese market, the Company’s intentions to seek out
additional opportunities to enter key international markets, Jaguar’s
plan to develop formulations of SB-300 in horses and species-specific
formulations of Neonorm™ in additional target species, and
the Company’s plan to develop formulations of Canalevia™ for
cats and dogs. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,” “plan,”
“aim,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this release are only predictions.
Jaguar has based these forward-looking statements largely on its current
expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to
a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond Jaguar’s
control. Except as required by applicable law, Jaguar does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20160907005165/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
